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Sir
I read with interest the report by Pronk and colleagues on a dose
escalation study of the combination chemotherapy of docetaxel
and ifosfamide (Pronk et al, 1998). They evaluated an alternating
sequence of ifosfamide 24-h infusion and docetaxel. Docetaxel
preceded 1 h before ifosfamide administration, and in the reverse
ifosfamide was followed by docetaxel with a 24-h interval. They
described that the maximum tolerated dose (MTD) was higher
when docetaxel was administered before ifosfamide than vice
versa and that this schedule was recommended for phase II studies.
I would be of the opinion that the sequence with higher MTD is
not always optimal. In vitro studies using human liver microsomes
showed that cytochrome P450 3A4 should be involved in both
metabolic pathways by detoxification of docetaxel and activation
of ifosfamide (Chang et al, 1993; Marre et al, 1996). This implies
that the metabolic activation of ifosfamide might be competitively
inhibited by the preceded docetaxel with the short interval. In
other words, the sequence with the higher MTD might result in a
lower anti-tumour activity than the reverse at the same doses of the
drugs. Other combination regimens, for example docetaxel plus
cisplatin or paclitaxel plus cyclophosphamide seem unlikely to
cause such interaction because of their different metabolic path-
ways. The combination of docetaxel and ifosfamide, however,
substantially differs from them.
A primary endpoint of phase I study is generally to find the
optimal dose of tested drugs, not to evaluate antitumour activity. In
this case, I consider that further phase II studies of both schedules
should be essential to determine the optimal sequence. Otherwise,
it would be inevitable to show the reason of their decision based on
pharmacokinetic data including active metabolites of ifosfamide.
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